Furaginum MAX US Pharmacia

GIF decision: Re-authorization for marketing

What does this decision mean?

  • Ponowne dopuszczenie do obrotu — The product has been re-authorized for marketing after earlier restrictions.

NIL testing showed that the product does not meet quality requirements due to a failed test for nitrosamine content: NDMA, indicating contamination of the product with a potentially carcinogenic compound. Potential effects: chronic exposure, increased cancer risk, possible other toxic effects.

Download the app and stay informed

Get instant notifications about recalled products and protect your family.

Furaginum MAX US Pharmacia
Risk Level
Critical
Manufacturer
US Pharmacia Sp. z o.o.
Batch Number
12872535
Notice Date
28.01.2026
View official statement

Related

Other Notices